Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020, specifically reporting a transaction notification dated November 4, 2020. The filing details a transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing is a transaction notification and does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
| Transaction Type | Instrument | Volume | Price |
|---|---|---|---|
| Purchase | Ordinary Shares (25 pence each) | 5,548 | £13.53 |
Material Changes
The filing reports a single transaction executed on November 3, 2020, on the London Stock Exchange (XLON). There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of a specific share purchase.
Key Facts for Investor Verification
- Insider Activity: Mr. J Ford, SVP & General Counsel, purchased 5,548 ordinary shares.
- Transaction Date: November 3, 2020.
- Transaction Price: £13.53 per share.
- Exchange: London Stock Exchange (XLON).
- Financial Data: No company-level financial performance data is provided in this filing.